Interview with Philippe Ranty, Managing Director, Actavis France
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
Address: Centre d’Affaires la Boursidière BP 50, 92357 le Plessis-Robinson, France ,France
Tel: +33 1 40 83 77 77
Web: http://www.actavis.com/en/default.htm
Actavis is the fifth largest generics company worldwide. In France, Actavis has been present since acquiring Labo Torlan in 2007. The groups domestic strategy can be characterized by three elements: a large product offer, a new approach of quality and customer relationship management and a strong involvement in sustainable development.
Actavis serves the French market through its Actavis France, Arrow Generiques and Medis businesses. The Company develops, manufactures and distributes a broad portfolio of products, including generic drugs for retail and hospital markets, OTC, cosmetics and mature products.
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
Pierre Banzet, President of Group Synerlab, one of the top ten French CMOs, discusses his group’s ambitious European expansion strategy, driven by their specialties in multi-dose, preservative-free eye drops, generics,…
The Director of the newly formed Necker Institute for Sick Children reveals how the inspiration behind INEM was to bring people together in order to create a common scientific policy…
Pfizer Global Established Products’ BU Head and Hospira’s Director of Institutional Affairs tell us about Pfizer’s recent major acquisition of Hospira, their post-merger strategy for increasing market access, as well…
The Head of the Department of Medical Oncology at the Pitié-Salpêtrière Hospital reveals how France is the only country in the world with universal and unlimited access to healthcare, how…
(© Sébastien Borda) The CEO of Novartis France reveals how the construction of a new French headquarters demonstrates a commitment to develop operations in the country, how the Huningue Biotechnology…
The general manager of Astellas France and president of LEEM, the French Pharmaceutical Companies Association, reveals how the pharmaceutical industry worldwide has to take into account what is a fair…
The President of Fefis, and the recently elected President of Medicen Paris Region, a Paris-based business cluster, talks about the need to build the future of the French health economy, not…
The director of GEMME reveals how the French generics market is young in comparison to other European countries – where generics were on the market twenty years before they became…
The Chairman & CEO of DBV Technologies reveals how they have developed a new therapeutic method and new technology in the form of a patch to treat various allergies. DBV received…
The President of Cristers discusses the history of generic drugs in France and what steps can be taken to increase generics penetration, while also outlining the ‘cooperative’ business model behind…
Yves Bur reveals how the motivation behind his political engagement has been to raise awareness around the importance of improving the social security system. Bur also explains why having a…
The General Manager of LEEM talks about the association’s strategy based on three key points, innovation, attractiveness and efficiency; how the Mediator affair has placed a question mark on the…
See our Cookie Privacy Policy Here
